Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

PF-05175157

PF-05175157 (PF-5175157) is a potennt Acetyl-CoA carboxylase (ACC) inhibitor with IC50 of 27 and 33 nM for hAAC1 and hACC2, respectively; shows concentration-dependent reductions in both skeletal muscle and liver malonyl-CoA with EC50 of 870 and 540 nM after 1 h following an acute oral dose in rats; demonstrates significant potential for the treatment of type 2 diabetes mellitus (T2DM) .Diabetes Phase 2 Discontinued (In Vitro) :PF-05175157 is broad spectrum acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 27.0±2.7, 33.0±4.1, 23.5±1.1 and 50.4±2.6 nM for ACC1 (human), ACC2 (human), ACC1 (rat) and ACC2 (rat), respectively. The in vitro metabolism of PF-05175157 (Compound 9) is evaluated in microsomes from rat, dog, and human hepatocytes. PF-05175157 is not metabolized in rat, dog, or human microsomes. PF-05175157 is also stable in human hepatocyte incubations, but is minimally metabolized by recombinant human CYP3A4 and CYP3A5. PF-05175157 inhibits formation of malonyl-CoA in a concentration-dependent manner with a potency (EC50=30 nM) in rat hepatocytes consistent with its potency against rat ACC1 (24 nM) . (In Vivo) :Oral administration (3 mg/kg) to rats and dogs show bioavailability of 40% and 54%, respectively, consistent with the low microsomal clearance and good solubility at low pH. Formation of the direct product of ACC, malonyl-CoA, in the skeletal muscle and liver of lean rats is assessed 1 h following an acute oral dose of PF-05175157, showing concentration-dependent reductions in both skeletal muscle and liver malonyl-CoA. At the nadir, quadriceps and liver malonyl-CoA levels are reduced by 76% and 89%, respectively. The EC50s for inhibition of quadriceps and liver malonyl-CoA are 870 and 540 nM, respectively, determined from unbind plasma concentrations of PF-05175157. Acute oral administration of PF-05175157 inhibits hepatic DNL in rats in an unbind plasma drug concentration-dependent manner. PF-05175157 inhibits up to 82% of the incorporation of [14C]acetate into [14C]lipids with an EC50 of 326 nM.

Product Specifications

CAS Number

1301214-47-0

Product Name Alternative

PF05175157 | PF-5175157

Purity

>98% (HPLC)

Solubility

DMSO : 30 mg/mL. 73.98 mM

Smiles

O=C1CC2 (CCN (C (C3=CC=C4N=C (C) NC4=C3) =O) CC2) CC5=C1N (C (C) C) N=C5

Molecular Formula

C23H27N5O2

Molecular Weight

405.49

Storage Conditions

Storage temperature: -20°C. Stability: ≥ 2 years

Notes

For research use only.

Other Product Names

1,4-Dihydro-1'-[ (2-methyl-1H-benzimidazol-6-yl) carbonyl]-1- (1-methylethyl) spiro[5H-indazole-5,4'-piperidin]-7 (6H) -one

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

KRT222P, CT (KRT222, KRT222P, KA21, Keratin-like protein KRT222, Keratin-222, Keratin-222 pseudogene) (APC) discontinued
037607-APC 200 µL

KRT222P, CT (KRT222, KRT222P, KA21, Keratin-like protein KRT222, Keratin-222, Keratin-222 pseudogene) (APC) discontinued

Sign In for Pricing
View Details
Recombinant Human VEGFC Protein
ARP5542-01 10 µg

Recombinant Human VEGFC Protein

Sign In for Pricing
View Details
Recombinant Human VEGFC Protein
ARP5542-02 50 µg

Recombinant Human VEGFC Protein

Sign In for Pricing
View Details
Recombinant Human VEGFC Protein
ARP5542-03 100 µg

Recombinant Human VEGFC Protein

Sign In for Pricing
View Details
Recombinant Human VEGFC Protein
ARP5542-04 1 mg

Recombinant Human VEGFC Protein

Sign In for Pricing
View Details
CY-09
C11337-5mg 5 mg

CY-09

Sign In for Pricing
View Details